Structural determinants for affinity enhancement of a dual antagonist peptide entry inhibitor of human immunodeficiency virus type-1.
about
Click chemistry in peptide-based drug designCovalent conjugation of a peptide triazole to HIV-1 gp120 enables intramolecular binding site occupancyProtein allostery, signal transmission and dynamics: a classification scheme of allosteric mechanisms.The active core in a triazole peptide dual-site antagonist of HIV-1 gp120.Probing the HIV gp120 envelope glycoprotein conformation by NMR.Antiviral breadth and combination potential of peptide triazole HIV-1 entry inhibitors.Peptide Triazole Inactivators of HIV-1 Utilize a Conserved Two-Cavity Binding Site at the Junction of the Inner and Outer Domains of Env gp120.Introducing metallocene into a triazole peptide conjugate reduces its off-rate and enhances its affinity and antiviral potency for HIV-1 gp120.The V1-V3 region of a brain-derived HIV-1 envelope glycoprotein determines macrophage tropism, low CD4 dependence, increased fusogenicity and altered sensitivity to entry inhibitorsHIV-1 Env gp120 structural determinants for peptide triazole dual receptor site antagonism.Peptide triazole inactivators of HIV-1: how do they work and what is their potential?A model of peptide triazole entry inhibitor binding to HIV-1 gp120 and the mechanism of bridging sheet disruptionNon-natural peptide triazole antagonists of HIV-1 envelope gp120.Chemical optimization of macrocyclic HIV-1 inactivators for improving potency and increasing the structural diversity at the triazole ring.Recognition of HIV-inactivating peptide triazoles by the recombinant soluble Env trimer, BG505 SOSIP.664.Cell-free HIV-1 virucidal action by modified peptide triazole inhibitors of Env gp120.Interactions of peptide triazole thiols with Env gp120 induce irreversible breakdown and inactivation of HIV-1 virions.
P2860
Q26853053-FFDCAC9A-589A-440A-83C5-F9906D4FB791Q33710476-8E49F9BA-97BF-4174-85A4-DE3A7FF76E5BQ33968222-0C013852-114C-4350-981F-1F8C8ED9AE41Q34558123-D6627AF1-84FA-4B75-90C7-9B9784205B69Q35085066-5DEDCCAD-D049-4DF4-AC9D-5AB2BF83E575Q35689392-84E3C411-499F-4CBF-8A3B-1C788A3562A8Q35835515-58A650F9-550E-4FDC-9B41-4913E9C8AE75Q36839845-2922C717-4352-4CC7-BD2B-38BF3853890FQ36957295-D51FC787-F912-4B15-BB4B-53CBD9AFB11DQ37063734-7389E4C2-D2D2-4EFF-81A2-95001E7B7875Q37081209-9B1F68C3-9616-41CD-88AB-025450E6A324Q37238636-166A20BA-7AD4-4BA0-BC1E-D6A6A632E8B8Q37260033-192B54C8-0750-4593-A57B-40B381D285F6Q38647724-5BB7F9D7-2D1A-4BA4-BC35-2EF728D91DE7Q38774504-09339E12-4805-4F38-9AE5-320C8162D999Q39516140-E4AFFE69-FCA7-4FC8-B764-386764328A48Q41846910-16C783D2-28E9-4DD5-9921-0E00A576346A
P2860
Structural determinants for affinity enhancement of a dual antagonist peptide entry inhibitor of human immunodeficiency virus type-1.
description
2008 nî lūn-bûn
@nan
2008 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Structural determinants for af ...... immunodeficiency virus type-1.
@ast
Structural determinants for af ...... immunodeficiency virus type-1.
@en
Structural determinants for af ...... immunodeficiency virus type-1.
@nl
type
label
Structural determinants for af ...... immunodeficiency virus type-1.
@ast
Structural determinants for af ...... immunodeficiency virus type-1.
@en
Structural determinants for af ...... immunodeficiency virus type-1.
@nl
prefLabel
Structural determinants for af ...... immunodeficiency virus type-1.
@ast
Structural determinants for af ...... immunodeficiency virus type-1.
@en
Structural determinants for af ...... immunodeficiency virus type-1.
@nl
P2093
P2860
P356
P1476
Structural determinants for af ...... immunodeficiency virus type-1.
@en
P2093
Amos B Smith
Arne Schön
Ernesto Freire
Ferit Tuzer
Fred C Krebs
Hosahudya Gopi
Irwin Chaiken
Isaac Zentner
Jeffrey C Klein
Judith LaLonde
P2860
P304
P356
10.1021/JM070814R
P407
P577
2008-04-11T00:00:00Z